


α-NETA

Cat. No.:	HY-138097
CAS No.:	115066-04-1
Molecular Formula:	C ₁₆ H ₂₀ INO
Molecular Weight:	369.24
Target:	Apoptosis; Cholinesterase (ChE); Aldehyde Dehydrogenase (ALDH); Chemerin Receptor
Pathway:	Apoptosis; Neuronal Signaling; Metabolic Enzyme/Protease; GPCR/G Protein
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (225.68 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.7083 mL	13.5413 mL	27.0827 mL
		5 mM	0.5417 mL	2.7083 mL	5.4165 mL
10 mM		0.2708 mL	1.3541 mL	2.7083 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC ₅₀ of 9 μM. α-NETA is a potent ALDH1A1 (IC ₅₀ =0.04 μM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC ₅₀ =84 μM) and acetylcholinesterase (AChE; IC ₅₀ =300 μM). α-NETA has anti-cancer activity ^{[1][2]} .	
IC₅₀ & Target	ALDH1	AChE
In Vitro	α-NETA (50-150 nM; 24 hours) decreases all cell lines viability in a dose-dependent manner ^[3] .	

α -NETA (2.5-10.0 $\mu\text{g}/\text{mL}$; 24 hours) leads to epithelial ovarian cancer (EOC) cell death associated with membrane blistering and cytoplasm leakage^[3].

α -NETA treatment increases EOC cell expression of pyroptosis-associated proteins^[3].

α -NETA is most potent in inhibiting aldehyde dehydrogenase 1 family, member A1 (ALDH1A1; IC_{50} =0.04 μM ; purified enzymes assay), followed by CMKLR1 (IC_{50} =0.375 μM for β -ARR2 recruitment; Cell-based assay) and G9a histone lysine methyltransferase (IC_{50} =0.50 μM ; purified enzymes assay). α -NETA selectively inhibits chemerin-stimulated CMKLR1 association with β -arrestin2^[2].

α -NETA possesses fluorescent characteristics (excitation spectrum: maxima 255 and 297 nm; emission spectrum: maximum 437 nm) of naphthyl moiety^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	Ho8910, Ho8910PM, A2780, and Iose80 cells
Concentration:	50, 100, 150 nM
Incubation Time:	24 hours
Result:	Decreased all cell lines viability in a dose-dependent manner.

Apoptosis Analysis^[3]

Cell Line:	Epithelial ovarian cancer (EOC) cell
Concentration:	2.5, 7.5, 10.0 $\mu\text{g}/\text{mL}$
Incubation Time:	24 hours
Result:	Led to EOC cell death associated with membrane blistering and cytoplasm leakage.

In Vivo

α -NETA (i.p.; 0.125 mg/kg; once every other day for 20 days) significantly decreases tumor volume and tumor weight^[3].

α -NETA (s.c. injection; 3 mg/kg or 10 mg/kg; daily; for 30 days) significantly delays the onset of EAE with 3 mg/kg, and completely suppresses clinical signs for an average of nine days with 10 mg/kg beyond the first appearance of disease in control female C57BL/6 mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nude mice with skov3 cells ^[3]
Dosage:	0.125 mg/kg
Administration:	IP; once every other day for 20 days
Result:	Significantly decreased tumor volume and tumor weight.

CUSTOMER VALIDATION

- Hypertension. 2024 Feb 15.
- Eur J Pharmacol. 2022 Oct 25;175343.
- BMC Endocr Disord. 2023 Jan 10;23(1):9.
- Research Square Preprint. 2023 Sep 18.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sastry BV, et al. Relationships between chemical structure and inhibition of choline acetyltransferase by 2-(alpha-naphthoyl)ethyltrimethylammonium and related compounds. *Pharmacol Res Commun*. 1988 Sep;20(9):751-71.
- [2]. Graham KL, et al. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. *PLoS One*. 2014 Dec 1;9(12):e112925.
- [3]. Qiao L, et al. α -NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway. *FASEB J*. 2019 Nov;33(11):12760-12767.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA